

Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar, M.G. Road No.6, Goregaon West.
Mumbai- 400 104. Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office: "Deepa - Lakshmi" 106, Kherapati Colony, Gwalior - 474002 (M.P.)

Independent Auditor's Review Report on Unaudited Quarterly and Year to Date Financial Results of Remedium Lifecare Limited (formerly known as Roxy Exports Limited) pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To,

**The Board of Directors of Remedium Lifecare Limited
(formerly known as Roxy Exports Limited)**

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Remedium Lifecare Limited (formerly known as Roxy Exports Limited)** ('the Company') for the quarter ended December 31, 2022 and year to date results for the period April 01, 2022 to December 31, 2022, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar, M.G. Road No.6, Goregaon West.
Mumbai- 400 104. Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com


Head Office: "Deepa - Lakshmi" 106, Kherapati Colony, Gwalior - 474002 (M.P.)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For TAORI SANDEEP & ASSOCIATES

Chartered Accountants

FRN: 007414C



Atul Jain

Partner

M. No. 048920



Place: Mumbai

Date: 07.02.2023

UDIN: 23048920BGWMAJ7090

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended December 31st, 2022


(₹ in Lakhs)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31st December, 2022	30th September, 2022	31st December, 2021	31st December, 2022	31st December, 2021	31st March, 2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from Operations	17647.75	15845.21	20604.98	43425.70	46450.34	50479.19
II. Other Income	2.37	157.23	0.00	159.61	0.00	0.00
III. Total Income (I + II)	17650.12	16002.44	20604.98	43585.31	46450.34	50479.19
IV. Expenses						
Cost of Material Consumed	0.00	0.00	20384.69	0.00	45920.34	49846.98
Purchases of Stock-in-trade	17029.42	14513.04	0.00	34543.36	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	314.21	1057.63	0.00	7484.56	0.00	0.00
Employee Benefits Expenses	39.60	15.89	16.48	69.65	37.34	53.32
Finance Costs	1.83	0.30	0.00	2.38	0.00	10.70
Depreciation and amortisation expenses	1.24	1.28	1.96	13.68	5.40	7.38
Other Expenses	111.65	44.30	133.18	299.89	263.14	408.30
Total Expenses (IV)	17497.96	15632.43	20536.30	42413.52	46226.22	50326.69
V. Profit/(Loss) before exceptional items and tax (III- IV)	152.17	370.01	68.68	1171.79	224.12	152.51
VI. Exceptional items	0.00	151.05	0.00	151.05	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	152.17	218.96	68.68	1020.74	224.12	152.51
VIII. Tax Expense						
(1) Current tax	0.00	0.00	0.00	0.00	0.00	45.06
(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	-0.33
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00	0.00
Total Tax	0.00	0.00	0.00	0.00	0.00	44.73
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	152.17	218.96	68.68	1020.74	224.12	107.78
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	152.17	218.96	68.68	1020.74	224.12	107.78
XIV. Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV)	152.17	218.96	68.68	1020.74	224.12	107.78
(Comprising Profit (Loss) and Other Comprehensive Income for the Period)						
XVI. Earnings per equity share (for continuing operation):						
(1) Basic	4.23	6.08	1.91	28.35	6.23	2.99
(2) Diluted	4.23	6.08	1.91	28.35	6.23	2.99
XVII. Earnings per equity share (for discontinued operation):						
(1) Basic	4.23	6.08	1.91	28.35	6.23	2.99
(2) Diluted	4.23	6.08	1.91	28.35	6.23	2.99
XVIII. Earnings per equity share (for discontinued & continuing operations)						
(1) Basic	4.23	6.08	1.91	28.35	6.23	2.99
(2) Diluted	4.23	6.08	1.91	28.35	6.23	2.99

Notes:

- The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on February 07, 2023. The Statutory Auditors have carried out their limited review for the above results.
- The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The results has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 07, 2023. The Results for the quarter and nine months ended December 31, 2022, have been reviewed by the statutory auditors.
- The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification
- As the Company's business activity falls within a single segment, therefore "Segment Reporting" is not applicable.

For Remedium Lifecare Limited


VILAS LOKHANDE
 (Whole Time Director)
 DIN : 01228041



Date: 07.02.2023
 Place : Mumbai